Sensus Healthcare Reports Q1 2025 Financial Results

Sensus Healthcare, Inc. ( (SRTS) ) has released its Q1 earnings. Here is a breakdown of the information Sensus Healthcare, Inc. presented to its investors.

Sensus Healthcare, Inc. is a medical device company that specializes in non-invasive and minimally-invasive treatments for skin conditions, focusing on oncological and non-oncological applications. The company is recognized for its innovative superficial radiotherapy (SRT) technology.

In the first quarter of 2025, Sensus Healthcare reported revenues of $8.3 million, with a net loss of $2.6 million. The company shipped 21 SRT systems and showcased its products at major dermatology conferences, highlighting its commitment to expanding its market presence and product offerings.

Key financial highlights include a decrease in revenues compared to the previous year, attributed to fewer units sold to a major customer. Operating expenses increased due to higher costs in sales, marketing, and research and development, which included lobbying efforts and product development. Despite these challenges, the company remains optimistic about future profitability.

Looking ahead, Sensus Healthcare’s management is confident in achieving profitability in the coming quarters. The company plans to continue its investment in research and development and expects significant contributions from its Fair Deal Agreement program in the latter half of the year. The management is optimistic about signing additional multisite FDA customers, which could bolster future revenues.